News Syntara Limited

Equities

SNT

AU0000312480

End-of-day quote Australian S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
0.017 ^AUD	+6.25%		+13.33%	-15.00%

Apr. 10	Syntara Reaches 50% Recruitment in Phase 2 Trial for Bone Marrow Cancer Treatment	MT
Feb. 29	Syntara Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Syntara Reaches 50% Recruitment in Phase 2 Trial for Bone Marrow Cancer Treatment	Apr. 09	MT
Syntara Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 28	CI
Syntara to Begin Phase Two Study for SNT-5505 Combination Therapy Later in 2024 After Government Grant	Feb. 13	MT
Transcript : Syntara Limited - Shareholder/Analyst Call	Jan. 30
Syntara Opens Up to AU$2 Million Share Purchase Plan	Dec. 29	MT
Syntara Starts Dosing Patients in Phase Two Trial of Drug Candidate	Dec. 12	MT
Syntara Receives AU$5.2 Million R&D Tax Rebate	Dec. 05	MT
Pharmaxis Doses First Patient in Phase Two Sleep Trial	Nov. 10	MT
University of Birmingham : Promising target for liver disease treatments identified; Inhibiting a protein involved in liver inflammation has the potential to reduce or stop fibrosis in patients with non-alcoholic steatohepatitis, trial finds	Nov. 08	AQ
Pharmaxis Ltd Reports Earnings Results for the First Quarter Ended September 30, 2023	23-10-31	CI
Transcript : Pharmaxis Ltd, Q1 2024 Earnings Call, Oct 31, 2023	23-10-30
Pharmaxis Sells Mannitol Business; Shares Fall 3%	23-10-18	MT
Arna Pharma Pty Ltd completed the acquisition of Mannitol respiratory business of Pharmaxis.	23-10-18	CI
BTC Health Arm to Continue Distributing Bronchitol, Aridol in Australia	23-10-04	MT
Pharmaxis to focus on clinical-stage drug development	23-10-03	AQ
Pharmaxis to Change Name Amid Restructure, Appoints Chair	23-10-03	MT
Transcript : Pharmaxis Ltd - Special Call	23-10-02
Arna Pharma Pty Ltd entered into definitive agreement to acquire Mannitol respiratory business of Pharmaxis.	23-10-02	CI
Australian Bourse Halts Trading in Pharmaxis’ Securities	23-10-02	MT
Pharmaxis Ltd Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Syntara Limited

Equities

SNT

AU0000312480

Summary

Filters